Print this page
Understanding the Role of p53 in the Development and Progression of Oligometastatic Castration-Sensitive Prostate Cancer.
Aim 1: Validate the prognostic and predictive utility of high-risk mutations in oligo mCSPC treated with metastasis-directed therapy (MDT).
Aim 2: Structure-function analysis of TP53 mutations for association with metastatic potential from individuals with oligo mCSPC.
Aim 3: Test pharmacologic targeting of mutant p53 with APR-246 on the growth and metastatic potential of isogenic prostate cancer cells in vitro and in vivo.
Protocol Number:
152102
Phase:
N/A
Applicable Disease Sites:
Prostate
Scope:
National
Participating Institutions:
- Rutgers Cancer Institute of New Jersey
- Principal Investigator
- Matthew Deek
- Principal Investigator
For further information about clinical trials, please contact us at 732-235-7356.